Brookfield mulls $7.4 bln bid for Spain's Grifols, El Confidencial says
Nov 18 (Reuters) -Canadian fund Brookfield BN.TO plans to offer about 7 billion euros ($7.4 billion) for Spanish drugmaker Grifols GRLS.MC after finishing due diligence, news website El Confidencial reported on Monday, citing sources close to the matter.
Brookfield is evaluating offering 10.5 euros per share in a public tender offer, El Confidencial said, below Grifols' closing market price on Friday of 11.125 euros.
The Canadian private equity firm said in September it was interested in launching a takeover bid jointly with the Grifols family, pending successful completion of due diligence.
The company has lost about 30% of its market value since January, when short-seller fund Gotham City Research accused Grifols of overstating earnings and understating debt, which Grifols denied.
Spokespeople at Brookfield and Grifols did not immediately respond to requests for comment.
($1 = 0.9486 euros)
Reporting by Javi West Larrañaga. Editing by Inti Landauro and Mark Potter
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
